SOLICITATION NOTICE
B -- Cancer Outcomes with Androegen Deprivation Therapy for Localized and Advanced Prostate Cancer
- Notice Date
- 8/2/2004
- Notice Type
- Solicitation Notice
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- Reference-Number-NCI-40120-NV
- Response Due
- 8/16/2004
- Archive Date
- 8/31/2004
- Point of Contact
- Deborah Moore, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
- E-Mail Address
-
dm170b@nih.gov, rs442i@nih.gov
- Description
- The National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS), Applied Research Program (ARP), Health Services & Economics Branch (HSEB) plans to enter into a sole source procurement with the Oregon Health & Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97239 for the services of Drs Tomasz Beer, Mark Garzotto and Motomi Mori, who are experts in prostate cancer research. Recent studies indicate that there has been increasing use of androgen deprivation (AD) as primary therapy for localized prostate cancer.(Cooperberg, Grossfeld et al. 2003) Neither the clinical outcomes, nor the implications for other health issues, have been well characterized in this setting. There is a growing awareness of the long-term morbidity associated with androgen deprivation including osteoporotic fractures as well as adverse changes in lipid profile and body composition, and possibly neurocognitive and psychiatric toxicity. The objectives of this study are 1) To characterize the clinical outcomes and their predictors in patients who were treated with primary androgen deprivation for clinically localized prostate cancer and for advanced prostate cancer. This work will be done in parallel with an analysis of quality of life outcomes in the same population led by NCI; 2) To describe the incidence and time to event for the following outcomes: PSA failure (confirmed with 2 rising PSAs), PSA nadir, local failure, distant failure, and cardiovascular complications, depression and treatment for depression, overall survival; 3) To assess the effects of co-morbidities, smoking, use of herbal supplements, vitamins and minerals, socioeconomic status, insurance status, race, and geographic location on outcomes. The aforementioned investigators of the Oregon Health & Science University have unique experience and background relevant to the development of research methods and analysis of prostate cancer outcomes necessary to carry out the research objectives as described above. This includes having extensive experience in clinical practice relevant for understanding relevant issues in prostate cancer care, since their own medical practice is focused on this disease. In addition they have a unique familiarity with the Prostate Cancer Outcomes Study (PCOS), which is the source of the data for the proposed study. They have been heavily involved in the analysis entitled ?The Use and Outcomes of Therapies for Erectile Dysfunction Following Clinically Localized Prostate Cancer: Results from the SEER Prostate Cancer Outcomes Study (PCOS)? in collaboration with NCI. Thus, the combination of their experience in clinical care, analysis of the proposed outcomes in prostate cancer patients treated with primary hormonal therapy, and their familiarity with the PCOS data set and procedures demonstrates that the investigators are uniquely able to carry out the proposed work. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI researcher to determine if the party can perform this requirement. An original and one copy of the capability statements must be received in the contracting office by 1:00 p.m. EDT, on August 16, 2004. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to dm170b@nih.gov . It is the vendor's responsibility to call (301) 402-4509 to insure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect call will be accepted. NAICS 541990; Size Standard 6M.
- Record
- SN00634727-W 20040804/040802211806 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |